End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.92 CNY | -1.40% | +1.86% | -10.38% |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.41 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.38% | 1.09B | - | ||
+2.80% | 103B | A- | ||
+1.20% | 67.05B | A- | ||
+44.29% | 40.4B | B | ||
+15.99% | 38.64B | B | ||
+3.89% | 32.41B | A- | ||
+6.82% | 19.17B | B- | ||
+12.32% | 16.76B | C+ | ||
+17.69% | 15.07B | B- | ||
+8.31% | 14.82B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 000059 Stock
- Ratings North Huajin Chemical Industries Co.,Ltd